Immunoglobulin G1 [de-450-lysine], anti-(human sodium-dependent phosphate transport protein 2B) (human-Mus musculus monoclonal XMT-1535 ?1-chain), disulfide with human-Mus musculus monoclonal XMT-1535 ?-chain, dimer, thioether with N-(2-carboxyethyl)carbamates 22-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-5,10,20-trioxo-13,16-dioxa-2,6,9,19-tetraazadocosanoates dextran, oxidized, reduced, esters with N,N-dimethyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(?R,?R,2S)-?-methoxy-?-methyl-2-pyrrolidinepropanoyl-N-[3-[(2S)-2-[[3-(carboxyamino)-1-oxopropyl]amino]-1-oxopropoxy]propyl]-L-phenylalaninamide
Platinum-sensitive Ovarian Cancer (UPGRADE-A)
Mersana Therapeuticsantibody_drug_conjugatePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
525 Active assets in the Platinum-sensitive Ovarian Cancer (UPGRADE-A) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TIL Inge Marie Svane | Phase 2 | BB |
Tisotumab Vedotin Seagen Inc. | Phase 2 | BB |
Olaparib Shandong University | Phase 4 | BB |
Carboplatin Fudan University | Phase 4 | BB |
OTL-38 On Target Laboratories, LLC | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →